GLAXOSMITHKLINE

Lobbying client · District of Columbia · filed 2026 to 2026

Biopharmaceutical manufacturer.

$70,000 Reported spend

3 Filings counted

1 Firms hired

0 Bills named

Spend is reported income plus in-house expenses across 3 filings. Everything on this page is grouped by the client's LDA id (71670), not by name.

Firms hired 1

MARSHALL & POPP, LLC $70,000 3 filings

Reported by year 1 year

2026 $70,000 3 filings

Issues lobbied 2

Pharmacy 3
Trade (domestic/foreign) 1

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 5

Centers For Medicare and Medicaid Services (CMS) 2
Food & Drug Administration (FDA) 2
Health & Human Services, Dept of (HHS) 2
HOUSE OF REPRESENTATIVES 2
SENATE 2

Recent filings 3 total

Q2

MARSHALL & POPP, LLC

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $50,000 income · posted Jul 9, 2026

View → Q1

MARSHALL & POPP, LLC

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $20,000 income · posted Apr 17, 2026

View → RR

MARSHALL & POPP, LLC

1st Quarter (Jan 1 - Mar 31) 2026 · posted Mar 9, 2026

View →

Foreign entities disclosed 1

GSK PLC United Kingdom named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0

Section 7 of the LD-2: a foreign company or government that owns part of the client, pays toward the lobbying, or benefits from it. Figures are the highest single disclosure across these filings, not a sum: the same stake is re-disclosed each quarter.

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.